Evidence of Lineage 1 and 3 West Nile Virus in Person with Neuroinvasive Disease, Nebraska, USA, 2023
Emily Davis
1, Jason Velez
1, Jeff Hamik, Kelly Fitzpatrick, Jacki Haley, Jeremy Eschliman, Amanda Panella, J. Erin Staples, Amy Lambert, Matthew Donahue, Aaron C. Brault, and Holly R. Hughes
Author affiliations: Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (E. Davis, J. Velez, K. Fitzpatrick, A. Panella, J.E. Staples, A. Lambert, A.C. Brault, H.R. Hughes); Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA (J. Hamik, M. Donahue); Two Rivers Public Health Department, Kearney, Nebraska, USA (J. Haley, J. Eschliman)
Main Article
Figure 2
Figure 2. Consensus sequences for lineage 1 and lineage 3 WNV in serum and after Vp1 in samples from a patient with neuroinvasive disease and evidence of lineage 1 and 3 WNV infection, Nebraska, USA, 2023. Lineage 1 and lineage 3 WNV are distinct at the consensus level compared with Vp1 and historical strains. A, B) The consensus sequence of lineage 1 WNV in serum was compared with that of Vp1 (A), and those 2 sequences were then compared with the prototypical North American lineage 1 WNV strain, NY99 (B). C) Serum lineage 3 WNV consensus sequence was compared with the partial lineage 3 WNV sequences determined from Vp1 and CSF and historical lineage 3 WNV strains. C, capsid; CSF, cerebrospinal fluid; E, envelope; NS, nonstructural; prM, premembrane; Vp1, Vero passage 1; WNV, West Nile virus.
Main Article
Page created: August 23, 2024
Page updated: September 23, 2024
Page reviewed: September 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.